📊 ADPT Key Takeaways
Is Adaptive Biotechnologies Corp (ADPT) a Good Investment?
Adaptive Biotechnologies demonstrates strong revenue growth (+54.8% YoY) with rapidly improving losses trending toward profitability, but operational cash flow remains deeply negative (-$9.5M) signaling unresolved cost structure challenges. Strong liquidity (3.35x current ratio, $77.6M cash) provides runway, but sustainability depends on achieving operational profitability before cash reserves deplete.
Adaptive Biotechnologies shows strong top-line momentum, with revenue up 54.8% year over year, and it maintains a solid liquidity position with current and quick ratios above 3x. However, the business remains meaningfully unprofitable, with negative operating margins, negative free cash flow, and weak interest coverage, so the core fundamental story still depends on converting rapid growth into durable earnings and cash generation.
Why Buy Adaptive Biotechnologies Corp Stock? ADPT Key Strengths
- Strong revenue growth of 54.8% YoY with $70.9M revenue demonstrates solid market demand and product-market fit
- Rapidly improving loss profile: net income improved 62.7% YoY and diluted EPS improved 63.9%, showing clear trajectory toward profitability
- Excellent liquidity position (current ratio 3.35x, quick ratio 3.22x) with $77.6M cash and moderate leverage (0.58x debt/equity) providing 12-18 month operational runway
- Revenue growth is very strong at 54.8% year over year, indicating improving commercial traction
- Liquidity is solid, supported by $70.50M of cash and current and quick ratios above 3x
- Leverage is manageable relative to equity, with debt-to-equity at 0.58x despite ongoing losses
ADPT Stock Risks: Adaptive Biotechnologies Corp Investment Risks
- Negative operating cash flow of -$9.5M despite 55% revenue growth indicates operational costs are not scaling efficiently with revenues
- Still unprofitable with -28.3% net margin; cannot service debt from operations (interest coverage -6.6x), creating dependency on cash reserves
- Biotech sector inherent risks: profitability path dependent on clinical pipeline success, regulatory approvals, and reimbursement decisions; high cash burn sustainability threshold
- 40 insider Form 4 filings in 90 days warrant scrutiny; cash burn rate may force dilutive capital raises if profitability not achieved within 18-24 months
- The company remains unprofitable, with a -20.6% operating margin and -21.5% net margin
- Operating cash flow and free cash flow are still negative, showing the business is not yet self-funding
- Negative interest coverage indicates earnings do not currently support debt servicing comfortably
Key Metrics to Watch
- Operating cash flow inflection point and path to positive operating cash flow breakeven
- Gross margin recovery (currently N/A) and operating expense ratio trends relative to revenue growth rate
- Cash runway depletion timeline and capital raise necessity; target is 18+ months to operating profitability
- Operating margin and net income trend
- Operating cash flow and free cash flow
Adaptive Biotechnologies Corp (ADPT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.35x current ratio provides a solid financial cushion.
ADPT Profit Margin, ROE & Profitability Analysis
ADPT vs Healthcare Sector: How Adaptive Biotechnologies Corp Compares
How Adaptive Biotechnologies Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Adaptive Biotechnologies Corp Stock Overvalued? ADPT Valuation Analysis 2026
Based on fundamental analysis, Adaptive Biotechnologies Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Adaptive Biotechnologies Corp Balance Sheet: ADPT Debt, Cash & Liquidity
ADPT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Adaptive Biotechnologies Corp's revenue has grown significantly by 79% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.56 indicates the company is currently unprofitable.
ADPT Revenue Growth, EPS Growth & YoY Performance
ADPT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $52.4M | -$20.0M | $-0.13 |
| Q3 2025 | $46.4M | $9.5M | $0.06 |
| Q2 2025 | $43.2M | -$25.6M | $-0.17 |
| Q1 2025 | $41.9M | -$29.9M | $-0.20 |
| Q3 2024 | $37.9M | -$32.1M | $-0.22 |
| Q2 2024 | $43.2M | -$46.2M | $-0.31 |
| Q1 2024 | $37.6M | -$47.5M | $-0.33 |
| Q3 2023 | $37.9M | -$45.3M | $-0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Adaptive Biotechnologies Corp Dividends, Buybacks & Capital Allocation
ADPT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Adaptive Biotechnologies Corp (CIK: 0001478320)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADPT
What is the AI rating for ADPT?
Adaptive Biotechnologies Corp (ADPT) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADPT's key strengths?
Claude: Strong revenue growth of 54.8% YoY with $70.9M revenue demonstrates solid market demand and product-market fit. Rapidly improving loss profile: net income improved 62.7% YoY and diluted EPS improved 63.9%, showing clear trajectory toward profitability. ChatGPT: Revenue growth is very strong at 54.8% year over year, indicating improving commercial traction. Liquidity is solid, supported by $70.50M of cash and current and quick ratios above 3x.
What are the risks of investing in ADPT?
Claude: Negative operating cash flow of -$9.5M despite 55% revenue growth indicates operational costs are not scaling efficiently with revenues. Still unprofitable with -28.3% net margin; cannot service debt from operations (interest coverage -6.6x), creating dependency on cash reserves. ChatGPT: The company remains unprofitable, with a -20.6% operating margin and -21.5% net margin. Operating cash flow and free cash flow are still negative, showing the business is not yet self-funding.
What is ADPT's revenue and growth?
Adaptive Biotechnologies Corp reported revenue of $70.9M.
Does ADPT pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
Where can I find ADPT SEC filings?
Official SEC filings for Adaptive Biotechnologies Corp (CIK: 0001478320) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADPT's EPS?
Adaptive Biotechnologies Corp has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ADPT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Adaptive Biotechnologies Corp has a HOLD rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ADPT stock overvalued or undervalued?
Valuation metrics for ADPT: ROE of -9.3% (sector avg: 15%), net margin of -28.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ADPT stock in 2026?
Our dual AI analysis gives Adaptive Biotechnologies Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ADPT's free cash flow?
Adaptive Biotechnologies Corp's operating cash flow is $-9.5M, with capital expenditures of $796.0K. FCF margin is -14.6%.
How does ADPT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -28.3% (avg: 12%), ROE -9.3% (avg: 15%), current ratio 3.35 (avg: 2).